According to Cumberland Pharmaceuticals, the newly approved regimen is expected to simplify administration and potentially reduce medication errors and dose-related reactions by combining ...
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a ...
Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).